ATE52263T1 - Verbindungen mit entzuendungshemmender aktivitaet, hergestellt durch komplexierung mit beta- cyclodextrin und pharmazeutische zusammensetzungen welche diese enthalten. - Google Patents
Verbindungen mit entzuendungshemmender aktivitaet, hergestellt durch komplexierung mit beta- cyclodextrin und pharmazeutische zusammensetzungen welche diese enthalten.Info
- Publication number
- ATE52263T1 ATE52263T1 AT84113923T AT84113923T ATE52263T1 AT E52263 T1 ATE52263 T1 AT E52263T1 AT 84113923 T AT84113923 T AT 84113923T AT 84113923 T AT84113923 T AT 84113923T AT E52263 T1 ATE52263 T1 AT E52263T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- complexation
- cyclodextrin
- beta
- pharmaceutical compositions
- Prior art date
Links
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract 2
- 239000001116 FEMA 4028 Substances 0.000 title 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 title 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 title 1
- 229960004853 betadex Drugs 0.000 title 1
- 238000010668 complexation reaction Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- QHWIONJPGUQMDX-UHFFFAOYSA-N 2-(4-hydroxy-2-methyl-1,1-dioxo-1lambda6,2-benzothiazin-3-yl)-N-pyridin-2-ylacetamide Chemical compound OC1=C(N(S(C2=C1C=CC=C2)(=O)=O)C)CC(=O)NC1=NC=CC=C1 QHWIONJPGUQMDX-UHFFFAOYSA-N 0.000 abstract 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 229940097362 cyclodextrins Drugs 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Pain & Pain Management (AREA)
- Polymers & Plastics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT19735/84A IT1196033B (it) | 1984-02-22 | 1984-02-22 | Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche |
| EP84113923A EP0153998B1 (de) | 1984-02-22 | 1984-11-17 | Verbindungen mit entzündungshemmender Aktivität, hergestellt durch Komplexierung mit beta-Cyclodextrin und pharmazeutische Zusammensetzungen welche diese enthalten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE52263T1 true ATE52263T1 (de) | 1990-05-15 |
Family
ID=11160778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT84113923T ATE52263T1 (de) | 1984-02-22 | 1984-11-17 | Verbindungen mit entzuendungshemmender aktivitaet, hergestellt durch komplexierung mit beta- cyclodextrin und pharmazeutische zusammensetzungen welche diese enthalten. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4603123A (de) |
| EP (1) | EP0153998B1 (de) |
| JP (1) | JPS60208979A (de) |
| KR (1) | KR870001960B1 (de) |
| AT (1) | ATE52263T1 (de) |
| AU (1) | AU550007B2 (de) |
| BE (1) | BE900836A (de) |
| CA (1) | CA1234106A (de) |
| DE (2) | DE153998T1 (de) |
| DK (1) | DK164911C (de) |
| ES (1) | ES536909A0 (de) |
| IE (1) | IE58231B1 (de) |
| IT (1) | IT1196033B (de) |
| MY (1) | MY101374A (de) |
| NZ (1) | NZ211114A (de) |
| PH (1) | PH22075A (de) |
| PT (1) | PT79997B (de) |
| SG (1) | SG53690G (de) |
| ZA (1) | ZA848156B (de) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU43290B (en) * | 1986-11-13 | 1989-06-30 | Lek Tovarna Farmacevtskih | Process for preparing inclusioned complex of ibuproxane with beta-cyclodextrine |
| IT1204725B (it) * | 1987-06-17 | 1989-03-10 | Edmond Pharma Srl | Complessi di inclusione del dipiridamolo con ciclodestrine |
| NZ225045A (en) * | 1987-07-01 | 1990-06-26 | Janssen Pharmaceutica Nv | Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent |
| US5017566A (en) * | 1987-12-30 | 1991-05-21 | University Of Florida | Redox systems for brain-targeted drug delivery |
| US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| DE3809808A1 (de) * | 1988-03-23 | 1989-10-05 | Hexal Pharma Gmbh & Co Kg | Feste, insbesondere festorale und rektale, etofenamat enthaltende arzneimittel |
| US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| IT1241088B (it) * | 1990-03-27 | 1993-12-29 | Chiesi Farma Spa | Procedimento per la preparazione di complessi piroxicam/ciclodestrina,prodotti ottenuti e loro composizioni farmaceutiche |
| US5180716A (en) * | 1990-08-01 | 1993-01-19 | The Regents Of The University Of California | Cyclodextrin complexes for neuraxial administration of drugs |
| DE69231457T2 (de) * | 1991-06-21 | 2001-05-23 | Takeda Chemical Industries Ltd | Zyklodextrin-Zusammensetzung enthaltend Fumagillol-Derivate |
| US20040014695A1 (en) * | 1992-06-19 | 2004-01-22 | Supergen, Inc. | Pharmaceutical formulation |
| US5602112A (en) | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
| IL111184A (en) * | 1993-10-08 | 2000-08-13 | Farmarc Nederland B V Of Cito | Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin |
| US5646131A (en) * | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
| IT1269578B (it) * | 1994-04-22 | 1997-04-08 | Chiesi Farma Spa | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base. |
| ZA959469B (en) * | 1994-11-15 | 1996-05-15 | South African Druggists Ltd | Pharmaceutical composition |
| US5824668A (en) * | 1996-11-07 | 1998-10-20 | Supergen, Inc. | Formulation for administration of steroid compounds |
| UA57734C2 (uk) | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
| IT1293764B1 (it) * | 1997-07-23 | 1999-03-10 | Chiesi Farma Spa | Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua |
| US6667056B2 (en) * | 1997-07-23 | 2003-12-23 | Chiesi Farmaceutici S.P.A. | Pharmaceutical compositions containing an effervescent acid-base couple |
| FR2786395A1 (fr) * | 1998-12-01 | 2000-06-02 | Virbac Sa | Compositions seches solubles en presence d'eau et evitant la reaction de maillard a l'etat sec, leur preparation et leurs applications |
| TWI242015B (en) | 1999-11-29 | 2005-10-21 | Akzo Nobel Nv | 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
| WO2002045713A2 (en) * | 2000-12-04 | 2002-06-13 | Sepracor, Inc. | Orally-bioavailable formulations of fentanyl and congeners thereof |
| GB0205253D0 (en) * | 2002-03-06 | 2002-04-17 | Univ Gent | Immediate release pharmaceutical granule compositions and a continuous process for making them |
| PT1374906E (pt) * | 2002-06-17 | 2007-07-24 | Chiesi Farma Spa | Um processo para a preparação de compostos de inclusão de piroxicam: beta-ciclodextrina |
| EP1582221A1 (de) * | 2004-03-31 | 2005-10-05 | Chiesi S.A. | Orale Pharmazeutische zusammensetzung zur Geschmacksmaskierung |
| DE602005027333D1 (de) | 2004-04-01 | 2011-05-19 | Pf Medicament | Einschlusskomplexe enthaltend piroxicam, ein cyklodextrin und arginin |
| PT1586310E (pt) * | 2004-04-15 | 2007-02-28 | Helm Ag | Processo para a preparação de adsorvatos de valsartan na forma de pó solto |
| US20060024922A1 (en) * | 2004-07-27 | 2006-02-02 | Da-Tung Wen | Method for cutting wafer |
| CN101123989B (zh) * | 2004-08-02 | 2010-12-15 | 奇斯药制品公司 | 制备吡罗昔康：β-环糊精包合物的方法 |
| FR2876910B1 (fr) | 2004-10-21 | 2007-04-13 | Pierre Fabre Medicament Sa | Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction |
| US20070010486A1 (en) * | 2005-07-06 | 2007-01-11 | Jeff Schwegman | Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins |
| US20070009531A1 (en) * | 2005-07-06 | 2007-01-11 | Branimir Sikic | Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar |
| US20070010487A1 (en) * | 2005-07-06 | 2007-01-11 | Jeff Schwegman | Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins |
| US20070010485A1 (en) * | 2005-07-06 | 2007-01-11 | Jeff Schwegman | Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins |
| US20070010478A1 (en) * | 2005-07-06 | 2007-01-11 | Branimir Sikic | Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer |
| GB0612695D0 (en) * | 2006-06-27 | 2006-08-09 | Univ Gent | Process for preparing a solid dosage form |
| CL2007003876A1 (es) * | 2007-12-28 | 2008-03-07 | Univ De Concepcion Y Lab Andro | Complejo de inclusion que esta formado por disulfiram y ciclodextrina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de la dependencia de alcohol y cocaina. |
| KR101383941B1 (ko) * | 2012-03-09 | 2014-04-10 | 동아에스티 주식회사 | 피록시캄 또는 약제학적으로 허용되는 그의 염과 히알루론산 또는 약제학적으로 허용되는 그의 염의 안정한 액상 조성물 및 그 제조방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2827452A (en) * | 1955-05-31 | 1958-03-18 | Univ Minnesota | Stabilization of materials |
| US3969338A (en) * | 1971-03-15 | 1976-07-13 | Institut National De La Recherche Agronomique | Protein obtained from cakes of vegetable origin |
| HU184066B (en) * | 1979-12-28 | 1984-06-28 | Chinoin Gyogyszer Es Vegyeszet | Plant growth regulating substance and process for preparing such compound |
| HU182217B (en) * | 1980-10-17 | 1983-12-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing inclusive complexes of cyclodextrines and strong inorganic oxyacids |
| JPS5838250A (ja) * | 1981-09-01 | 1983-03-05 | Teikoku Chem Ind Corp Ltd | 複合体 |
| JPS58126810A (ja) * | 1981-12-24 | 1983-07-28 | Kaken Pharmaceut Co Ltd | 抗炎症眼科用液剤およびその製法 |
| JPS5920230A (ja) * | 1982-07-19 | 1984-02-01 | チバ−ガイギ−・アクチエンゲゼルシヤフト | ピルプロフエン含有薬剤 |
-
1984
- 1984-02-22 IT IT19735/84A patent/IT1196033B/it active Protection Beyond IP Right Term
- 1984-10-17 BE BE0/213844A patent/BE900836A/fr not_active IP Right Cessation
- 1984-10-18 ZA ZA848156A patent/ZA848156B/xx unknown
- 1984-10-19 ES ES536909A patent/ES536909A0/es active Granted
- 1984-11-13 US US06/670,979 patent/US4603123A/en not_active Expired - Lifetime
- 1984-11-17 DE DE198484113923T patent/DE153998T1/de active Pending
- 1984-11-17 AT AT84113923T patent/ATE52263T1/de not_active IP Right Cessation
- 1984-11-17 EP EP84113923A patent/EP0153998B1/de not_active Expired - Lifetime
- 1984-11-17 DE DE8484113923T patent/DE3482041D1/de not_active Expired - Lifetime
- 1984-11-20 JP JP59245845A patent/JPS60208979A/ja active Granted
-
1985
- 1985-02-11 IE IE32585A patent/IE58231B1/en not_active IP Right Cessation
- 1985-02-13 NZ NZ211114A patent/NZ211114A/en unknown
- 1985-02-18 AU AU38923/85A patent/AU550007B2/en not_active Expired
- 1985-02-19 PH PH31877A patent/PH22075A/en unknown
- 1985-02-19 DK DK076085A patent/DK164911C/da not_active IP Right Cessation
- 1985-02-21 PT PT79997A patent/PT79997B/pt unknown
- 1985-02-21 CA CA000474850A patent/CA1234106A/en not_active Expired
- 1985-02-21 KR KR1019850001074A patent/KR870001960B1/ko not_active Expired
-
1987
- 1987-09-30 MY MYPI87002570A patent/MY101374A/en unknown
-
1990
- 1990-07-11 SG SG536/90A patent/SG53690G/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU550007B2 (en) | 1986-02-27 |
| PT79997B (en) | 1987-01-13 |
| IT8419735A0 (it) | 1984-02-22 |
| ES8504789A1 (es) | 1985-05-01 |
| DE3482041D1 (de) | 1990-05-31 |
| AU3892385A (en) | 1985-08-29 |
| CA1234106A (en) | 1988-03-15 |
| DK164911B (da) | 1992-09-07 |
| KR850006133A (ko) | 1985-10-02 |
| DK164911C (da) | 1993-01-18 |
| PT79997A (en) | 1985-03-01 |
| ES536909A0 (es) | 1985-05-01 |
| US4603123A (en) | 1986-07-29 |
| EP0153998B1 (de) | 1990-04-25 |
| EP0153998A2 (de) | 1985-09-11 |
| IE850325L (en) | 1985-08-22 |
| BE900836A (fr) | 1985-02-15 |
| JPH0370705B2 (de) | 1991-11-08 |
| JPS60208979A (ja) | 1985-10-21 |
| IT1196033B (it) | 1988-11-10 |
| IE58231B1 (en) | 1993-08-11 |
| ZA848156B (en) | 1985-06-26 |
| DE153998T1 (de) | 1986-04-10 |
| KR870001960B1 (ko) | 1987-10-23 |
| EP0153998A3 (en) | 1987-01-14 |
| DK76085D0 (da) | 1985-02-19 |
| SG53690G (en) | 1990-11-23 |
| PH22075A (en) | 1988-05-20 |
| DK76085A (da) | 1985-08-23 |
| MY101374A (en) | 1991-10-23 |
| NZ211114A (en) | 1987-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE52263T1 (de) | Verbindungen mit entzuendungshemmender aktivitaet, hergestellt durch komplexierung mit beta- cyclodextrin und pharmazeutische zusammensetzungen welche diese enthalten. | |
| DE3688114D1 (de) | Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate. | |
| EP0300526A3 (de) | Cyclodextrine enthaltende antivirale Arzneimittel | |
| DE3586206D1 (de) | Metoprololsuccinat und dieses enthaltende pharmazeutische zusammensetzung. | |
| ATE253941T1 (de) | Zusammensetzung mit erhöhter lagerstabilität enthaltend cyclodextrin und wirkstoffe oder wirkstoff-vorstufen, die in wasserunlösliche komponenten zersetzt werden | |
| AU591245B2 (en) | A deodorant composition and use thereof | |
| FI904230A0 (fi) | Akrylsyraderivat. | |
| DE69914084D1 (de) | Phenylacetylglutamin, phenylacetylisoglutamin, und/oder phenylacetat zur behandlung von neoplastischen erkrankungen | |
| ATE95070T1 (de) | Pharmazeutische zusammensetzung mit gehalt an einer mischung von kollagen und einem antiseptischen und/oder entzuendungshemmenden wirkstoff und verfahren zu ihrer herstellung. | |
| KR860003830A (ko) | 가용화한 백금화합물 및 그 제조방법 | |
| ATE167804T1 (de) | Verwendung von nickel und bromide ionen für die behandlung von psoriasis | |
| DK0559612T3 (da) | Dioxolanderivater som pesticider | |
| ATE39348T1 (de) | Riechstoffe und ihre herstellung. | |
| IT8025850A0 (it) | Coadiuvante per promuovere l'absorbimento di sostanze farmacologicamente attive attraverso il retto, e composizione farmaceutica che lo comprendono. | |
| ATE43598T1 (de) | Verbindungen mit aktivitaet gegen aggregation von blutplaettchen, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen. | |
| DE3667472D1 (de) | Analoge von hypokalzemischen polypeptiden, welche den kalziumgehalt des koerpers schonen, deren herstellung, deren verwendung als arznei und diese enthaltende zusammensetzungen. | |
| DE3669713D1 (de) | Alkylaminoamide und ihre salze, ihre herstellung, ihre verwendung als arzneimittel und diese verbindungen enthaltende zusammensetzungen. | |
| JPS56147704A (en) | Dermatological composition | |
| FR2652086B1 (fr) | Compose nouveau d'origine vegetale, derive de l'acide cafeique, l'oraposide; composition a usage therapeutique et composition dermato-cosmetique le contenant. | |
| KR940014266A (ko) | 제오라이트를 이용한 분뇨 처리방법 | |
| KR890007717A (ko) | 약제 디스펜서 | |
| Strichartz | The binding of saxitoxin to nerve tissue and its antagonism by various agen. | |
| ES8303451A1 (es) | "procedimiento para la preparacion de d-homo-4,17-androstadien-3-ona". | |
| KR850007241A (ko) | 인분을 주재로 한 고단위 비료 제법 | |
| DE59009647D1 (de) | Stabilisiertes Reagenzgemisch. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| EELA | Cancelled due to lapse of time |